The stock of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has increased by 12.67 when compared to last closing price of 22.18.Despite this, the company has seen a gain of 30.43% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-17 that Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company’s core investment thesis is centered around its cutting-edge research and its ability to derive revenue from its collaborations. The potential approval of its first vaccine will work as a proof-of-concept for its mRNA platform and will likely raise the market expectations.

Is It Worth Investing in Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Right Now?

The price-to-earnings ratio for Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) is above average at 6.91x. The 36-month beta value for ARCT is also noteworthy at 2.56. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for ARCT is $62.00, which is $37.01 above than the current price. The public float for ARCT is 24.31M, and at present, short sellers hold a 20.52% of that float. The average trading volume of ARCT on November 20, 2023 was 383.81K shares.

ARCT’s Market Performance

ARCT’s stock has seen a 30.43% increase for the week, with a 21.31% rise in the past month and a -19.75% fall in the past quarter. The volatility ratio for the week is 11.18%, and the volatility levels for the past 30 days are at 6.89% for Arcturus Therapeutics Holdings Inc The simple moving average for the past 20 days is 28.83% for ARCT’s stock, with a -1.33% simple moving average for the past 200 days.

Analysts’ Opinion of ARCT

Many brokerage firms have already submitted their reports for ARCT stocks, with William Blair repeating the rating for ARCT by listing it as a “Outperform.” The predicted price for ARCT in the upcoming period, according to William Blair is $71 based on the research report published on July 24, 2023 of the current year 2023.

ARCT Trading at 6.97% from the 50-Day Moving Average

After a stumble in the market that brought ARCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.80% of loss for the given period.

Volatility was left at 6.89%, however, over the last 30 days, the volatility rate increased by 11.18%, as shares surge +23.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.82% lower at present.

During the last 5 trading sessions, ARCT rose by +30.43%, which changed the moving average for the period of 200-days by +9.08% in comparison to the 20-day moving average, which settled at $19.64. In addition, Arcturus Therapeutics Holdings Inc saw 47.35% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ARCT starting from Chivukula Pad, who sale 5,000 shares at the price of $18.72 back on Nov 01. After this action, Chivukula Pad now owns 499,448 shares of Arcturus Therapeutics Holdings Inc, valued at $93,602 using the latest closing price.

Chivukula Pad, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc, sale 5,000 shares at $25.61 during a trade that took place back on Oct 02, which means that Chivukula Pad is holding 504,448 shares at $128,062 based on the most recent closing price.

Stock Fundamentals for ARCT

Current profitability levels for the company are sitting at:

• +8.44 for the present operating margin

The net margin for Arcturus Therapeutics Holdings Inc stands at +4.54. The total capital return value is set at 5.25, while invested capital returns managed to touch 3.26. Equity return is now at value 46.66, with 26.44 for asset returns.

Based on Arcturus Therapeutics Holdings Inc (ARCT), the company’s capital structure generated 35.05 points at debt to equity in total, while total debt to capital is 25.96. Total debt to assets is 21.04, with long-term debt to equity ratio resting at 11.18. Finally, the long-term debt to capital ratio is 8.28.

When we switch over and look at the enterprise to sales, we see a ratio of 1.27, with the company’s debt to enterprise value settled at 0.58. The receivables turnover for the company is 67.20 and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.18.

Conclusion

In summary, Arcturus Therapeutics Holdings Inc (ARCT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.